Aude Chapuis, MD
WT1-targeting adoptive T cell therapy for AML patients at high risk for relapse
Although aggressive chemotherapy and stem cell transplantation can cure AML, toxicity is significant and most patients still don’t survive long-term. Transplantation cures are largely due to leukemia-killing immune T cells from the donor. We can genetically engineer a patient’s own T cells that may be safer and destroy AML better.